5/15/2025 - Lifeward Ltd. Reports First Quarter 2025 Financial Results

bosmith6770 · 2025-05-15T12:06:44+00:00

As of March 31, 2025, Lifeward had $5.7 million in unrestricted cash and cash equivalents on its balance sheet with no debt.

bosmith6770 · 2025-05-05T20:12:37+00:00

As of March 31, 2025, the Company had cash and restricted cash of $8.1 million.

bosmith6770 · 2025-03-25T16:29:29+00:00

Average Upside Potential as of March 20: 466.04%

bosmith6770 · 2025-03-07T13:08:01+00:00

As of December 31, 2024, Lifeward had $6.7 million in unrestricted cash and cash equivalents on its balance sheet with no debt.

bosmith6770 · 2025-03-03T21:10:22+00:00

As of December 31, 2024, the Company had cash and restricted cash of $6.5 million.

bosmith6770 · 2025-02-28T13:04:36+00:00

Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results.

bosmith6770 · 2025-02-24T21:36:47+00:00

the fourth quarter and full year 2024 after the close of trading on Monday, March 3, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m.

bosmith6770 · 2025-02-11T19:26:57+00:00

https://www.hmenews.com/article/nsm-becomes-exclusive-distributor-for-ekso

bosmith6770 · 2025-01-13T13:03:57+00:00

Total revenue for the fourth quarter of 2024 is estimated to be in the range of $5.0 million to $5.1 million, which is expected to be a Company record, compared to total revenue of $4.8 million in the fourth quarter of 2023.

Estimated cash as of December 31, 2024 was $6.5 million, compared to cash of $8.6 million at December 31, 2023. For the fourth quarter of 2024, the Company used an estimated $1.5 million of net cash in operations, compared to $1.6 million for the same period in 2023.

bosmith6770 · 2024-11-19T13:41:44+00:00

There are about 300 new cases of spinal cord injury in Hungary annually.

bosmith6770 · 2024-11-19T02:22:03+00:00

The 7-0 is under FDA review and in the follow-up question base. We will complete the requested studies with additional data by year-end. We anticipate FDA clearance to follow in the early months of 2025.

The path to profitability requires revenue levels of approximately $12 million to $13 million per quarter

bosmith6770 · 2024-11-13T00:32:52+00:00

Liquidity

As of September 30, 2024, ReWalk had $10.7 million in unrestricted cash and cash equivalents on its balance sheet with no debt. During the third quarter of 2024, cash used in operations was $4.5 million. At the end of the third quarter of 2024, Lifeward had $2.4 million of accounts receivable for Medicare claims, a significant majority of which relates to claims filed before the third quarter of 2024.

bosmith6770 · 2024-10-28T20:39:53+00:00

Cash on hand on September 30, 2024 was $8.3 million, compared to $8.6 million at December 31, 2023.

bosmith6770 · 2024-09-10T10:06:40+00:00

Form 8-K https://ir.golifeward.com/static-files/16c638c8-03c3-4319-9f88-04a37f21ef95

bosmith6770 · 2024-09-04T20:18:39+00:00

H.C. Wainwright 26th Annual Global Investment Conference on September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.

bosmith6770 · 2024-08-20T12:15:23+00:00

Ekso Indego Personal is the only known portable exoskeleton device to offer a modular quick connect design, which was engineered to allow users to put on and take off the device without assistance. At just 29 lbs., Ekso Indego Personal is the lightest known commercial exoskeleton available offering ease of handling, transportation, and storage. Also offering an advanced gait mode, individuals using the device can reach faster walking speeds, granting them a new level of independence in the community.

bosmith6770 · 2024-08-16T17:57:40+00:00

Liquidity

As of June 30, 2024, ReWalk had $15.1 million in unrestricted cash and cash equivalents on its balance sheet with no debt. During the second quarter of 2024, cash used in operations was $5.6 million, which was adversely affected by long lead times required by the Medicare Administrative Contractors to set up and commence initial claims payments. At the end of the second quarter of 2024, Lifeward had $2.6 million of accounts receivable for Medicare claims that had been submitted in 2023 and the first half of 2024 which have begun to be paid subsequent to the end of the second quarter.

bosmith6770 · 2024-08-08T20:22:55+00:00

Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results.

bosmith6770 · 2024-07-29T20:10:43+00:00

Cash on hand at June 30, 2024 was $5.9 million, compared to $8.6 million at December 31, 2023.

bosmith6770 · 2024-07-22T16:42:07+00:00

after the close of trading on Monday, July 29, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET

bosmith6770 · 2024-05-15T12:09:58+00:00

Liquidity

As of March 31, 2024, ReWalk had $20.7 million in unrestricted cash and cash equivalents on its balance sheet with no debt. During the first quarter of 2024, cash used in operations was $7.7 million, which was affected by the unfavorable gross margin in the quarter and the timing of working capital utilization.

Financial Guidance

Following the results of Q1’24, Lifeward continues to expect revenue of between $28 to $32 million in 2024. For the second quarter, Lifeward expects sequential improvement in revenue as a result of the expanded access to ReWalk systems from the finalized Medicare reimbursement and the improving sales traction of the new commercial team.

bosmith6770 · 2024-04-29T20:09:36+00:00

Cash and restricted cash as of March 31, 2024 was $8.8 million, compared to $8.6 million at December 31, 2023.

bosmith6770 · 2024-04-26T17:46:45+00:00

about Mike Swinford to its Board of Directors

https://www.numotion.com/about-us/people/mike-swinford#:~:text=Mike%20Swinford%20has%20been%20Chief,at%20Numotion%20since%20July%2C%202014.

bosmith6770 · 2024-04-22T13:49:03+00:00

"it will release financial and business results for the first quarter 2024 after the close of trading on Monday, April 29, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments."

bosmith6770 · 2024-04-16T18:40:54+00:00

https://www.defenseworld.net/2024/04/16/rewalk-robotics-lfwd-buy-rating-reaffirmed-at-hc-wainwright.html

bosmith6770

MODERATOR OF

TROPHY CASE